Jan 10, 2024 / 05:45PM GMT
Eric Joseph JPMorgan Securities LLC-Analyst
Great. Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan and our next presenting company at Enanta Pharmaceuticals. Presenting on behalf of the company is CEO, Jay Luly is a Q&A after the presentation, we'll bring mikes around for those who have questions and folks tuning in via webcast, feel free to submit questions via the portal.
Jay Luly Enanta Pharmaceuticals - Inc. - President, CEO & Director
With that, Jay, thanks for joining Thanks, Eric. Before I begin, I want to remind you that I'll be making some forward-looking statements and for a summary of the risks associated with these statements, please see our filings on SEC.gov and on our website.
For those of you less familiar with Enanta, we are a company that has a sort of a legacy in virology. We're working on multiple different viral targets more recently have expanded into respiratory viruses, including RSV and STARS CoV two. And today I will also be talking about our our recent recently announced entry into
Enanta Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers